What ChondroFiller injection costs in the UK

ChondroFiller injection in the UK is priced on a fixed three-tier model determined by the area of the cartilage defect, as measured at clinical assessment:

• £3,000 — one box, treating a defect of approximately 3 cm²
• £5,500 — two boxes, extending coverage to approximately 4.5 cm²
• £8,000 — three boxes, covering up to approximately 6 cm²

Severe or complex Grade III/IV cases may rise to £9,800. Because defect size is established through imaging review and clinical examination, patients cannot select a tier in advance — the appropriate quantity of product is confirmed at assessment.

Each tier is fully inclusive: it covers the pre-injection consultation, imaging review, real-time ultrasound guidance, the ChondroFiller product itself, intravenous antibiotic cover, and a six-week follow-up appointment. No extras are billed separately.

Combination pathway costs

Patients with more advanced joint disease sometimes receive ChondroFiller alongside Arthrosamid, a non-regenerative polyacrylamide hydrogel that cushions and lubricates the joint rather than rebuilding cartilage tissue. The two products serve mechanistically distinct roles: ChondroFiller provides the regenerative scaffold; Arthrosamid addresses the joint environment. This combination is priced at £6,000. Adding autologous mesenchymal stem cells (the Tri-Active pathway) raises the total to £11,000.

For context, these figures sit at the accessible lower end of the UK cartilage regeneration market, which runs from around £4,000 for microfracture to £28,000 for single-stage implantation procedures.

What the price includes

Private musculoskeletal care in the UK typically generates multiple invoices — consultation, imaging, the procedure itself, consumables, and follow-up billed as separate line items. The bundled structure described in the pricing tiers above is a meaningful departure from that norm, and it matters for planning: the figure agreed at the outset is the figure settled at the end, with no reconciliation required against a post-treatment itemised bill.

The cost level itself reflects the nature of the product rather than clinic overhead. ChondroFiller is a CE-marked Class III medical device — the highest regulatory risk category under European medical device law — manufactured by Meidrix Biomedicals GmbH in Germany and imported into the UK under prescription. Class III designation requires the most rigorous conformity assessment prior to market placement, and both the regulatory pathway and the importation process contribute meaningfully to the per-box cost. Patients comparing the price against a standard hyaluronic acid or corticosteroid injection are, in effect, comparing different regulatory and product categories, not simply different clinic fee structures.

NHS funding for ChondroFiller injection

ChondroFiller injection sits entirely outside NHS provision. There is no NICE technology appraisal, no ICB commissioning policy, no pilot programme, and no active public-funding application in England or the devolved nations. Patients cannot access it through a GP referral — the full cost must be budgeted for privately from the outset.

This position is consistent with the product's reception across Europe. Neither the German Krankenkasse statutory insurance system nor Austrian public health insurance reimburses ChondroFiller injection, despite the product being manufactured in Germany by Meidrix Biomedicals GmbH. The route to access throughout Europe is private pay or private medical insurance; there is no publicly funded pathway in the product's country of origin or anywhere else it is currently offered.

Patients who cannot self-fund and who meet strict eligibility criteria do have one NHS-funded cartilage repair option available to them: Autologous Chondrocyte Implantation (ACI), approved under NICE TA477 in October 2017. ACI is a two-stage surgical procedure and is not equivalent to ChondroFiller injection, but it is the only publicly funded cartilage regeneration pathway in the UK, offered at specialist centres including RJAH NHS Foundation Trust in Oswestry, which accepts referrals nationally.

What some UK private insurers may contribute toward the cost of ChondroFiller injection is addressed in the next section.

Private medical insurance and ChondroFiller

Private medical insurance coverage for ChondroFiller injection is not a simple yes or no. No major UK insurer includes it as a standard policy benefit: Bupa and AXA do not routinely fund it, and patients should not assume their policy extends to the procedure. That said, case-by-case pre-authorisation has been granted, and in clinical practice approvals are reported most often through Bupa, Aviva, and WPA.

The reason partial coverage remains possible is that ChondroFiller injection maps to established CCSD billing codes that already appear on UK insurer fee schedules: W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy). Quoting these codes directly when contacting an insurer removes ambiguity about what the procedure involves and gives the claim the best chance of being assessed correctly rather than declined on procedural grounds.

The practical step for any patient with a private medical insurance policy is to request written pre-authorisation before committing to treatment — not after the appointment has been booked and certainly not after the procedure. Verbal assurances from an insurer's telephone helpline do not constitute approval and are not binding. If pre-authorisation is declined, the full cost falls to the patient regardless of what was discussed informally. Insurer reimbursement positions do change, so patients should verify current coverage directly with their provider; the guidance here reflects clinical practice as of October 2025.

ACI: the NHS-funded cartilage repair alternative

For patients who cannot meet the cost of private treatment, ACI represents the only realistic NHS-funded cartilage regeneration pathway — though the procedure differs substantially from a ChondroFiller outpatient injection in both its staging and its demands on the patient.

ACI involves two separate operations. In the first, a small biopsy of healthy cartilage is harvested from a low-load area of the affected joint under general anaesthetic. Those cells are then sent to a laboratory for expansion over several weeks before the patient returns for a second procedure, during which the cultured chondrocytes are implanted into the defect and secured beneath a periosteal patch or membrane. Recovery from the reimplantation stage typically requires a significant period of protected weight-bearing and structured rehabilitation — a meaningful commitment that contrasts with the outpatient injection pathway.

Eligibility is not open. NICE TA477 sets defined criteria: in broad terms, ACI is reserved for patients with a symptomatic, full-thickness focal cartilage defect in the knee of a specified size range who have not responded to prior treatments. Patients with diffuse degenerative change or with other joint pathology that has not been addressed may not qualify. A GP or NHS MSK clinician can advise whether a referral is appropriate.

RJAH NHS Foundation Trust in Oswestry is one of the few UK hospitals offering ACI as a funded service and accepts patients from across the country. Enquiries about NHS eligibility and referral should be directed to a GP or treating clinician in the first instance.

The only certified UK centre for ChondroFiller injection

Across all the pricing and funding detail above, one practical question remains: where in the UK is ChondroFiller injection actually available?

At present, the only documented certified centre for the procedure is the London Cartilage Clinic at 66 Harley Street, London W1. The clinic holds ICRS Teaching Centre of Excellence status — a designation from the International Cartilage Repair Society recognising both clinical volume and training commitment. Professor Paul Y.F. Lee, who leads the service, was the first clinician in the UK to offer ChondroFiller as an outpatient injection rather than as a theatre-based procedure.

There is no publicly available list of additional certified ChondroFiller providers in the UK beyond this single centre. Manufacturer Meidrix Biomedicals GmbH does not appear to maintain a UK centre directory accessible to patients. This matters in practice: patients who encounter ChondroFiller pricing elsewhere — whether from another clinic's website or from informal recommendations — should verify provider credentials, ICRS standing, and clinical volume carefully before committing. The technique requires precise ultrasound-guided placement, and outcomes are sensitive to how and by whom the injection is delivered.

For patients wanting to explore whether they are suitable candidates, a clinical assessment through the London Cartilage Clinic is the verified starting point for this injectable pathway in the UK.